Prognostic factors of long-term CD4+ count-guided interruption of antiretroviral treatment

Autor: Sarmati, L, Andreoni, Carolina, Nicastri, E, Tommasi, C, Buonomini, A, D'Ettorre, G, Corpolongo, A, Dori, L, Montano, M, Volpi, A, Narciso, P, Vullo, Vincenzo, Andreoni, M, Mar, J. MED V. I. R. O. L., PMID PUBMED INDEXED FOR MEDLINERELATED CITATIONS, .
Jazyk: angličtina
Rok vydání: 2009
Předmět:
CD4-Positive T-Lymphocytes
Male
Reduced risk
Time Factors
Human immunodeficiency virus (HIV)
RNA directed DNA polymerase inhibitor
HIV Infections
medicine.disease_cause
immunology
Antiretroviral Therapy
Highly Active
proteinase inhibitor
virus DNA
adult
article
CD4 lymphocyte count
controlled study
female
highly active antiretroviral therapy
human
Human immunodeficiency virus 1 infection
major clinical study
male
prognosis
scoring system
survival rate
treatment duration
blood
CD4+ T lymphocyte
clinical trial
Human immunodeficiency virus infection
methodology
middle aged
multicenter study
prospective study
time
treatment outcome
treatment withdrawal
Adult
CD4 Lymphocyte Count
DNA
Viral
Female
Humans
Middle Aged
Prognosis
Prospective Studies
Treatment Outcome
Withholding Treatment
Medicine
Viral
Infectious Diseases
Viral load
Settore MED/17 - Malattie Infettive
Antiretroviral Therapy
ANTIRETROVIRAL AGENTS
Virology
Multicenter trial
Antiretroviral treatment
In patient
Highly Active
business.industry
DNA
Treatment interruption
business
Popis: Aim of the study was to determine predictors of the duration of antiretroviral treatment interruption in patients infected with HIV. This pilot prospective, open-label, multicenter trial comprised 62 HIV-seropositive subjects who decided voluntarily to interrupt therapy after two or more years of successful HAART. The primary end-point was the time to patients being free of therapy before reaching a CD4+ cell count
Databáze: OpenAIRE
Externí odkaz: